Arat A, Cil B E, Vargel I, Turkbey B, Canyigit M, Peynircioglu B, Arat Y O
Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA, and Hacettepe University Hospitals, Ankara, Turkey.
AJNR Am J Neuroradiol. 2007 Aug;28(7):1409-14. doi: 10.3174/ajnr.A0547.
Various techniques and materials have been used for the endovascular treatment of craniofacial high-flow arteriovenous vascular malformations, because their rarity precludes standardization of their treatment. The aim of this retrospective review is to assess Onyx as the primary embolic agent in the treatment of these vascular malformations.
Six patients with arteriovenous fistulas and 3 with arteriovenous malformations (AVMs) of the head and neck region were treated with intra-arterial (IA)/direct percutaneous injections of Onyx. Adjunctive maneuvers used during embolization included external compression of the arterial feeders or venous outflow (6 patients), balloon assist (4 patients), and direct embolization of the draining vein remote to the fistula site (1 patient). n-butyl-2-cyanoacrylate (n-BCA) was used in addition to Onyx for rapid induction of thrombosis in a large venous pouch (1 patient) and for cost containment purposes (1 patient). Four patients were treated surgically after the embolization.
There were no neurologic complications secondary to the embolization procedure. The arteriovenous shunt was eliminated in all of the fistulous lesions and 2 of the 3 AVMs. The embolization was incomplete in 1 patient with a large AVM who declined further endovascular or surgical procedures. Untoward events included 2 instances of catheter entrapment (of 9 IA injections), blackish skin discoloration necessitating surgical revision in 1 patient, and difficulty of balloon deflation/wire withdrawal during a balloon-assisted embolization.
Onyx appears to be a safe and effective liquid embolic agent for use in the treatment of craniofacial high-flow vascular malformations with distinct advantages and disadvantages compared with n-BCA.
由于颅面部高流量动静脉血管畸形较为罕见,难以实现治疗的标准化,因此已采用多种技术和材料对其进行血管内治疗。本回顾性研究的目的是评估Onyx作为这些血管畸形治疗的主要栓塞剂的效果。
对头颈部动静脉瘘患者6例和动静脉畸形(AVM)患者3例采用动脉内(IA)/直接经皮注射Onyx进行治疗。栓塞过程中采用的辅助操作包括对动脉供血支或静脉引流进行外部压迫(6例)、球囊辅助(4例)以及对远离瘘口部位的引流静脉进行直接栓塞(1例)。除Onyx外,还使用了正丁基-2-氰基丙烯酸酯(n-BCA),用于在一个大的静脉囊袋中快速诱导血栓形成(1例)以及控制成本(1例)。4例患者在栓塞后接受了手术治疗。
栓塞过程未引发神经系统并发症。所有瘘性病变以及3例AVM中的2例的动静脉分流均被消除。1例患有大型AVM的患者拒绝进一步的血管内或外科手术,栓塞不完全。不良事件包括9次IA注射中有2次发生导管嵌顿、1例患者因皮肤变黑需要进行手术修复,以及1例在球囊辅助栓塞过程中出现球囊放气/导丝回撤困难。
Onyx似乎是一种安全有效的液体栓塞剂,可用于治疗颅面部高流量血管畸形,但与n-BCA相比有明显的优缺点。